Drug profile · INN
saquinavir mesylate
INVIRASE
saquinavir mesylate (INVIRASE) is a human immunodeficiency virus type 1 protease inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — saquinavir mesylate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
saquinavir mesylate (INVIRASE) is a human immunodeficiency virus type 1 protease inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Human immunodeficiency virus type 1 protease inhibitor
Primary target: Human immunodeficiency virus type 1 protease
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is saquinavir mesylate?
saquinavir mesylate (INVIRASE) is a human immunodeficiency virus type 1 protease inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for saquinavir mesylate?
INVIRASE is a marketed brand name for saquinavir mesylate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of saquinavir mesylate?
saquinavir mesylate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.